E

Excel Medical Clinical Trials | Boca Raton, FL

Research site
(Unclaimed)
Location
7900 Glades Road, suite 400, Boca Raton, Florida, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

31 of 50
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling
Non-Alcoholic Fatty Liver Disease
Drug: Resmetirom

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: MGL-3196

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Enrolling
Alzheimer's Disease
Mental Disorders
Drug: Donanemab
Drug: Placebo

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Placebo in 1.5ml
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fract...

Enrolling
Heart Failure With Preserved Ejection Fraction
Heart Failure
Drug: LY3540378
Drug: Placebo

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) effects of olezarsen (formerly known...

Active, not recruiting
Familial Chylomicronemia Syndrome
Drug: Olezarsen

The purpose of this study is to evaluate the effect of olezarsen (formerly known as AKCEA-APOCIII-LRx) on the percent change in fasting triglycerides...

Active, not recruiting
Familial Chylomicronemia Syndrome
Drug: Olezarsen
Locations recently updated

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Enrolling
Severe Hypertriglyceridemia
Drug: Placebo
Drug: Olezarsen

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejec...

Active, not recruiting
Heart Failure With Preserved Ejection Fraction
Obesity
Other: Placebo
Drug: Tirzepatide

The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic St...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: Tirzepatide

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment...

Active, not recruiting
Type 2 Diabetes
Drug: Tirzepatide
Drug: Antihyperglycemic medication

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

The purpose of this study is to assess the change in 24-hour ambulatory blood pressure monitoring (ABPM) between baseline (Day 0) and Day 120 followi...

Enrolling
Hypogonadism
Drug: Natesto

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

Trial conditions

Fatty Liver (14 trials)
Non-alcoholic Fatty Live... (14 trials)
Cardiovascular Diseases (12 trials)
Atherosclerosis (8 trials)
Diabetes Mellitus (6 trials)
Type 2 Diabetes Mellitus (6 trials)
Liver Diseases (5 trials)
Hypercholesterolemia (4 trials)
Hyperlipoproteinemia Typ... (4 trials)
Hypertriglyceridemia (4 trials)

And 33 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems